The 62 rating InvestorsObserver gives to I-Mab ADR (IMAB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, IMAB’s 62 overall rating means the stock scores better than 62 percent of all stocks.
IMAB has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on IMAB!
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With I-Mab ADR Stock Today?
I-Mab ADR (IMAB) stock has gained 4.45% while the S&P 500 is lower by -0.07% as of 12:52 PM on Monday, Nov 13. IMAB has gained $0.07 from the previous closing price of $1.57 on volume of 490,243 shares. Over the past year the S&P 500 is higher by 11.49% while IMAB is lower by -63.64%. IMAB lost -$3.69 per share the over the last 12 months.
Click Here to get the full Stock Report for I-Mab ADR stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
